Company Profile

SUVEN PHARMACEUTICALS LTD.

NSE : SUVENPHARBSE : 543064ISIN CODE : INE03QK01018Industry : Pharmaceuticals & DrugsHouse : Private
BSE530.90-32.15 (-5.71 % )
PREV CLOSE (Rs.) 563.05
OPEN PRICE (Rs.) 567.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 54968
TODAY'S LOW / HIGH (Rs.)526.75 567.00
52 WK LOW / HIGH (Rs.)292 574.45
NSE532.35 -30.65 (-5.44 % )
PREV CLOSE(Rs.) 563.00
OPEN PRICE (Rs.) 564.80
BID PRICE (QTY) 532.35 (203 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 467876
TODAY'S LOW / HIGH(Rs.) 528.50 567.30
52 WK LOW / HIGH (Rs.)291.6 574.5

Company News

Date Heading Details
11-Jun-2021 Suven Pharmaceuticals enters into agreement with CSIR-IICT <p align="justify">Suven Pharmaceuticals (SPL), CSIR-Indian Institute of Chemical Technology (CSIR-IICT), Hyderabad and CSIR-National Institute of Interdisciplinary Science &amp; Technology, Thiruvananthapuram have entered into an agreement for the process technology transfer and manufacturing of the anti-COVID drug, Molnupiravir and 2-DG. </p><p align="justify">The agreements between the parties involve a total fee of Rs 8 lakh plus taxes for the grant of the licenses on non-exclusive basis to SPL. As per the agreement, CSIR IICT also would provide the process know how for the manufacture of new anti-COVID drug 2-DG to treat moderately and severely COVID infected patients to reduce their oxygen dependency.</p><p align="justify">Suven Pharmaceuticals is a bio-pharmaceutical company, incorporated with the object of being engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies. <br></p>
11-Jun-2021 Suven Pharmaceuticals jumps on entering into agreement with CSIR-IICT <p align="justify">Suven Pharmaceuticals is currently trading at Rs. 501.00, up by 20.15 points or 4.19% from its previous closing of Rs. 480.85 on the BSE.</p><p align="justify">The scrip opened at Rs. 495.20 and has touched a high and low of Rs. 514.35 and Rs. 495.20 respectively. So far 48835 shares were traded on the counter.</p><p align="justify">The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 565.00 on 26-Apr-2021 and a 52 week low of Rs. 152.50 on 12-Jun-2020.</p><p align="justify">Last one week high and low of the scrip stood at Rs. 523.90 and Rs. 460.00 respectively. The current market cap of the company is Rs. 12732.07 crore.</p><p align="justify">The promoters holding in the company stood at 60.00%, while Institutions and Non-Institutions held 12.45% and 27.55% respectively.</p><p align="justify">Suven Pharmaceuticals (SPL), CSIR-Indian Institute of Chemical Technology (CSIR-IICT), Hyderabad and CSIR-National Institute of Interdisciplinary Science &amp; Technology, Thiruvananthapuram have entered into an agreement for the process technology transfer and manufacturing of the anti-COVID drug, Molnupiravir and 2-DG. </p><p align="justify">The agreements between the parties involve a total fee of Rs 8 lakh plus taxes for the grant of the licenses on non-exclusive basis to SPL. As per the agreement, CSIR IICT also would provide the process know how for the manufacture of new anti-COVID drug 2-DG to treat moderately and severely COVID infected patients to reduce their oxygen dependency.</p><p align="justify">Suven Pharmaceuticals is a bio-pharmaceutical company, incorporated with the object of being engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies. <br></p>
08-Jun-2021 Corporate Action-Board to consider Dividend 2. Dividend The Board recommended a final dividend of Rs. 1.00 per equity share of face value of Rs 1/- each for the year 2020-2021. 3. e-Annual GeneralMeeting and Record date (i). The 3rd e-Annual General Meeting of the members of the Company will be held on Tuesday, August 31, 2021 through VC/ OAVM. (ii).The Board approved the August 17, 2021 as record date for the purposes of the Annual General Meeting and final dividend. The final dividend will be paid on andfrom September 07, 2021, within 30 days from the date of approval by members in the AGM.
01-Jun-2021 Suven Pharmaceuticals board to consider financial results & final dividend <p align="justify">Suven Pharmaceuticals has informed that a Meeting of the Board of Directors of the Company will be held on June 08, 2021, to consider and approve the Audited Financial Results (Standalone and Consolidated) of the Company under Ind AS for the fourth quarter and for the year ending March 31, 2021; and to consider and recommend a final dividend, if any, for the financial year ending March 31, 2021. Further note that trading window for dealing in the securities of the Company is already closed from April 01, 2021 as per PIT Code of the Company. Trading window will be opened from June 11, 2021.</p><p align="justify">The above information is a part of company's filings submitted to BSE.<br></p>
01-Jun-2021 Board Meeting Intimation for Intimation Of Board Meeting Of The Company To Be Held On Tuesday, The 8Th June, 2021 Suven Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/06/2021 ,inter alia, to consider and approve 1) To consider and approve the Audited Financial Results (Standalone and Consolidated) of the Company under Ind AS for the fourth quarter and for the year ending March 31, 2021. 2) To consider and recommend a final dividend, if any, for the financial year ending March 31, 2021. Please further note that TRADING WINDOW for dealing in the securities of the company is already closed from 01st April, 2021 as per PIT Code of the Company. Trading window will be opened from 11th June, 2021.
01-Jun-2021 Board to consider FY 21 results & Final Dividend on June 08, 2021 Suven Pharmaceuticals Ltd has informed BSE that a Meeting of the Board of Directors of the Company will be held on June 08, 2021, inter alia, to consider and approve the following matter(s): 1. To consider and approve the Audited Financial Results (Standalone and Consolidated) of the Company under Ind AS for the fourth quarter and for the year ending March 31, 2021. 2. To consider and recommend a final dividend, if any, for the financial year ending March 31, 2021. Further note that TRADING WINDOW for dealing in the securities of the Company is already closed from April 01, 2021 as per PIT Code of the Company. Trading window will be opened from June 11, 2021.
10-Feb-2021 Suven Pharmaceuticals informs about outcome of board meeting <DIV align=justify><SPAN>Suven Pharmaceuticals has informed that the Board of Directors of the company, at its meeting held today February 10, 2021, approved the following along with other business matters: Took on record and approved the attached Un-audited Standalone and Consolidated Financial Results prepared under Ind AS for the quarter and nine months ended 31st December, 2020 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 along with Limited Review Reports of the Statutory Auditors. The Board has also declared an interim dividend of Re 1.00 per equity share of face value of Re 1 each for the year 2020-2021. The Board approved the Record Date, 18th February, 2021 notified by the Company for the purpose of payment of interim dividend to the eligible shareholders. The above said dividend will be paid on or before 11th March, 2021.</DIV><SPAN><DIV align=justify><BR></DIV><DIV align=justify><SPAN>The above information is a part of company's filings submitted to BSE.</DIV><DIV><BR></DIV>
31-Oct-2020 Suven Suven Pharmaceuticals informs about press release <DIV align=justify><SPAN>Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, Suven Pharmaceuticals&nbsp;<SPAN>has informed that it has enclosed the copies of the newspaper advertisements regarding to Financial Results of the Company for the quarter and half-year ended September 30, 2020. The advertisements as appeared on October 31, 2020 in Business Standard and Andhra Prabha (Telugu). The above information will also be hosted on the website of the Company at: https://www.suvenpharm.com/index.php/investors/corporate-info/advertisements.</DIV><SPAN><DIV align=justify><BR></DIV><DIV align=justify><SPAN>The above information is a part of company's filings submitted to BSE.&nbsp;</DIV>